Navigation Links
Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
Date:4/26/2008

NTRON were "flu-like" symptoms, occurring in approximately 50% of patients, which may decrease in severity as treatment continues. Application site disorders were common (47%), but all were mild (44%) or moderate (4%) and no patient discontinued, and included injection site inflammation and reaction (i.e., bruise, itchiness, irritation). Injection site pain was reported in 2% of patients receiving PEGINTRON. Alopecia (thinning of the hair) is also often associated with alpha interferons including PEGINTRON.

Psychiatric adverse events, which include insomnia, were common (57%) with PEGINTRON but similar to INTRON A (58%). Depression was most common at 29%. Suicidal behavior including ideation, suicidal attempts, and completed suicides occurred in 1% of patients during or shortly after completing treatment with PEGINTRON.

The following serious or clinically significant adverse events have been reported at a frequency less than 1% with PEGINTRON or interferon alpha: Severe decreases in neutrophil or platelet counts, hypothyroidism, hyperglycemia, hypotension, arrhythmia, ulcerative and hemorrhagic colitis, development or exacerbation of autoimmune disorders including thyroiditis, RA, systemic lupus erythematosus, psoriasis, pulmonary disorders (dyspnea, pulmonary infiltrates, pneumonitis and pneumonia, some resulting in patient deaths), urticaria, angioedema, bronchoconstriction, anaphylaxis, retinal hemorrhages, and cotton wool spots.

In the PEGINTRON/REBETOL combination trial, the incidence of serious adverse events was 17% in the PEGINTRON/REBETOL groups compared to 14% in the INTRON A/ REBETOL group. The incidence of severe adverse events in the PEGINTRON/REBETOL combination therapy trial was 23% in the INTRON A/REBETOL group and 31-34% in the PEGINTRON/REBETOL groups. Dose reductions due to adverse reactions occurred in 42% of patients receiving PEGINTRON (1.5 mcg/kg)/REBETOL and in 34% of those receiving INTRON A/REBETOL.

In a study wi
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
2. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
3. Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
4. Final Data From the SEISMIC Trial Suggest Safety, Efficacy of Autologous Stem- Cell Therapy for Treating Congestive Heart Failure
5. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
6. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
7. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
8. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
9. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
10. BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
11. Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 2015  Two mass spectrometry technologies MALDI ... their effectiveness is established, according to biotechnology ... says that while mass spectrometry (mass spec ... in proteomic biomarker discovery and validation, mass ... techniques has struggled to elucidate molecular distribution ...
(Date:2/26/2015)... Feb. 26, 2015  Tandem Diabetes Care®, Inc. (NASDAQ: ... manufacturer of the t:slim® and t:flex™ Insulin Pumps, today ... 5,250,000 shares of its common stock at a price ... proceeds to Tandem from this offering are expected to ... and other estimated offering expenses payable by Tandem. All ...
(Date:2/26/2015)... VIEW, Calif. , Feb. 26, 2015  IRIDEX Corporation ... release its fourth quarter and full year 2014 financial results ...   In conjunction with the release, the Company will host ... p.m. Eastern Time on Thursday, March 5, 2015 ... business developments. Interested parties may access the live ...
Breaking Medicine Technology:Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 2Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 3Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 2Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 3IRIDEX Announces Fourth Quarter and Full Year 2014 Conference Call and Release Date 2
... NORTHRIDGE, Calif., Jan. 4, 2012 Daily doses of ... significantly improved menopausal symptoms, including significantly reducing hot flash ... in postmenopausal Japanese women published in the peer-reviewed ... is believed that S -equol, produced from the ...
... MEDICAL CORP. (NYSE:CMN) announced today that Andrew A. ... Needham & Company, LLC  14th Annual Growth Conference. The ... Wednesday, January 11, 2012 at The New York Palace ... the presentation. In addition, Mr. Krakauer and Seth R. ...
Cached Medicine Technology:New Fermented Soy Ingredient Containing S-equol Significantly Reduced Hot Flash Frequency 2New Fermented Soy Ingredient Containing S-equol Significantly Reduced Hot Flash Frequency 3New Fermented Soy Ingredient Containing S-equol Significantly Reduced Hot Flash Frequency 4New Fermented Soy Ingredient Containing S-equol Significantly Reduced Hot Flash Frequency 5New Fermented Soy Ingredient Containing S-equol Significantly Reduced Hot Flash Frequency 6New Fermented Soy Ingredient Containing S-equol Significantly Reduced Hot Flash Frequency 7
(Date:2/28/2015)... (PRWEB) February 28, 2015 March—also ... good time to remind ourselves and others that ... say Atlantic NeuroSurgical Specialists (ANS). , Concussions are ... account for 75% of TBIs. There are 1.6-3.8 ... may sound benign, but it is a brain ...
(Date:2/28/2015)... 2015 Indosoft Inc , developers ... Asterisk, are pleased to announce the development of Q-Suite ... 5.8 versions of Q-Suite, this new version will include ... of new features to the leading edge call center ... 5.9 will add features to enhance security and protection. ...
(Date:2/28/2015)... 28, 2015 The Mesothelioma Applied ... awards at the International Symposium on Malignant Mesothelioma on ... at the Hyatt Regency Bethesda in Bethesda, Maryland. The ... work and commitment to the mission to cure mesothelioma. ... will be presented to Miriam Ratner. Miriam runs the ...
(Date:2/28/2015)... Dr. Perry Patel , a ... recently announced a special offer for the Zoom!® Chairside ... for new and established patients at his Pismo Beach dentist office. ... white smile, Dr. Patel and his staff are offering ... from the regular price of $450. , Zoom! whitening ...
(Date:2/28/2015)... Kaylie Corrigan, Outdoor Supervisor at ... and current student obtaining her Masters degree in social ... forum in psychoeducation on substance use for teens at ... part of her studies. , “Even though these students ... counseling at the high school and junior high school ...
Breaking Medicine News(10 mins):Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 2Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 3Health News:Indosoft Proudly Announces Q-Suite 5.9 Call Center Software for Asterisk 2Health News:Cancer Research Foundation Honors Award Recipients 2Health News:Cancer Research Foundation Honors Award Recipients 3Health News:Cancer Research Foundation Honors Award Recipients 4Health News:Pismo Beach Dentist Announces Special for Zoom! Teeth Whitening 2Health News:Staff at Arizona Drug Addiction Treatment Center Starts Teen Sobriety Support Group at Local High School 2
... the University of California, San Francisco (UCSF) Medical Center has ... as healthy brain cells begin to form tumors. The ... common type of brain tumor, at its earliest stage, when ... have to prove safe and effective in clinical trials, a ...
... of an oral tablet or vaginal gel containing antiretroviral ... modified because an interim review found that the study ... tenofovir, marketed under the trade name Viread, is effective., ... that the Vaginal and Oral Interventions to Control the ...
... HealthDay Reporter , TUESDAY, Sept. 27 (HealthDay News) ... doesn,t slow decline in thinking skills, a new study ... study participants, risk of death, the researchers found. ... twice as likely to suffer mental impairment as those ...
... LAFAYETTE, Ind. - Purdue University scientists believe they have found ... Xiaoqi Liu, an assistant professor of biochemistry and member ... Liu are focusing on the function of a gene called ... Plk1 is also an oncogene, which tends to mutate and ...
... diagnostic test for Alzheimer,s disease (AD), scientists have discovered that ... of a protein linked to pregnancy years before showing symptoms. ... Theo Luider and colleagues explain that more than ... are rising with the graying of the population. Doctors can ...
... Breast cancer cells that mutate to resist drug treatment ... the drugs as they penetrate the cell membrane making ... Researchers have found a new way to break that ... breast cancer cells to forcibly activate a heat-shock protein called ...
Cached Medicine News:Health News:How normal cells become brain cancers 2Health News:NIH modifies 'VOICE' HIV prevention study in women 2Health News:Super-Tight Blood Sugar Control May Not Ease Mental Decline in Diabetics 2Health News:Super-Tight Blood Sugar Control May Not Ease Mental Decline in Diabetics 3Health News:Gene may be good target for tough-to-kill prostate cancer cells 2Health News:Scientists shut down pump action to break breast cancer cells' drug resistance 2Health News:Scientists shut down pump action to break breast cancer cells' drug resistance 3
Designed as an excellent form of primary suspension...
... the constant demands of mobilizing patients quickly. ... necessary to fit bilateral KAFO's.,The complete kit ... knee joints , 4 Copolymer thigh support ... bands , Ortho-wick™ Padding for thigh , ...
... controlled compression and cold, the Calf Cryo/Cuff ... designed cuff provides complete calf coverage for ... a single cuff, or with a cooler ... The Cooler is available separately and can ...
... lightweight orthosis is designed to comfortably ... while allowing unobstructed motion of the ... custom fit the splint may be ... using a heat gun. One cotton ...
Medicine Products: